European biotechnology company Valneva SE ("Valneva") and UK company BliNK Therapeutics Ltd ("BliNK Therapeutics") announced today the closing of the transaction creating BliNK Biomedical SAS, a private company specialised in the discovery of innovative monoclonal antibodies.
The new company is owned by Valneva, Kurma Biofund I (founding investor of BliNK Therapeutics), funds managed by Idinvest Partners, Cancer Research Technology (CRT) and BliNK Therapeutics’ founders.
BliNK Therapeutics’ technology has been developed by Facundo Batista, Head of the Lymphocyte Interaction Laboratory at Cancer Research UK's London Research Institute.
Trogenix Ltd today emerged from stealth mode to unveil its therapeutic platform for treating aggressive cancers. It raised a seed financing round earlier this year, led by 4BIO Capital and including investment from IQ Capital, Cancer Research Horizons, the US National Brain Tumor Society, AIN Ventures and Old College Capital.
Mosaic Therapeutics, Ltd, a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, announces it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA.
Cancer Research Horizons and Lean Life Sciences, together with Manchester Cancer Research Centre (MCRC) and over 20 specialist contract research organisations have launched the Oncology Development Programme (ODP2) to identify and accelerate novel oncology innovations into commercially attractive assets.
